BioCentury
ARTICLE | Company News

Refine Technology, Thermo Fisher, China National Pharmaceutical Group deal

July 30, 2012 7:00 AM UTC

Cell culture company Refine partnered with Sinopharm's Wuhan Institute of Biological Products to improve the yield and reduce the cost of vaccine manufacturing using Refine's ATF System. The ATF System is a cell retention device that uses Alternating Tangential Flow technology from a diaphragm to provide more reliable and efficient cell separation. The deal initially includes an undisclosed Wuhan vaccine, which is slated to enter clinical development for an undisclosed indication this year, and may be expanded. Details were not disclosed. ...